benzimidazole derivative, bm601, a novel inhibitor of hepatitis b virus and hbsag secretion：苯并咪唑衍生物，bm601，一种新型的抑制乙型肝炎病毒和hbsag的分泌.pdf

Antiviral Research 107 (2014) 6–15 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevi /locate/antiviral Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion Yi-Bin Xu a, Li Yang a, Gui-Feng Wang a, Xian-Kun Tong a, Ya-Juan Wang a, Ye Yu a, Jing-Feng Jing a, Chun-Lan Feng a, Pei-Lan He a, Wei Lu b,⇑, Wei Tang a,⇑, Jian-Ping Zuo a,c,⇑ a Laboratory of Immunopharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China b Institute of Drug Discovery and Development, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, China c Shanghai University of Traditional Chinese Medicine, China a r t i c l e i n f o a b s t r a c t Article history: Hepatitis B virus (HBV) belongs to the Hepadnaviridae family. HBsAg, greatly outnumbered mature virion, Received 25 January 2014 has been mysterious since the discovery of HBV. A novel benzimidazole derivative, BM601, is identified Revised 13 March 2014 inhibiting the secretion of HBV virions and HBsAg, with 50% effective concentration of 0.6 lM and Accepted 6 April 2014 1.5 lM, as well as 50% cytotoxicity concentration of 24.5 lM. It has no effect on transcription, protein Available online 15 April 2014 production, nucleocapsid formation or intracellular HBV DNA synthesis. Immunofluorescence an